Search Results
Search results for "Dr. Juan Jose Fung"
Results found for "Dr. Juan Jose Fung"
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
structure and activation mechanisms of GPCRs, the biotech investment community has injected significant funding Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum cavity, achieving complete blockade at the highest dose level.
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
1984 (Cerione et al. 1984), where reconstitution of purified β2-adrenergic receptors from guinea pig lung of adjustability in terms of pharmacological effects, allowing for the administration of substantial doses
- Targeting Intracellular Allosteric Sites in GPCRs
of adjustability in terms of pharmacological effects, allowing for the administration of substantial doses
- Four Reasons to Measure GPCR Signaling Bias in Drug Discovery
Dose-response curves for incretin agonists on GLP-1 and GIP receptors.
- Odorant receptors – a bit of smell for drug discovery
ORs are highly expressed by olfactory sensory neurons of the nose where they are activated by different analyses, have indicated that OR genes are also expressed in non-olfactory tissues including the testis, lung epithelial cells proliferation via activation by β-ionone which initiates prostate cancer cell cycle arrest (Jones In non-small-cell lung cancer OR2J3 activation induced apoptosis and inhibited cell proliferation and
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
. 👉 Biotech founders often delay critical business moves, hiring, BD outreach, or funding decisions,
- Overview of adhesion GPCRs self-activation
Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,
- The One Reason Why Biotech Startups Fail More Often Than They Should
Science evolves in parallel with regulatory funding pressure and team growth.  Without it, even strong science slowly loses direction. 👉 Understanding why biotech startups fail  is
- The Real Cost of Strategic Overload in Biotech
The scientific ambition may be impressive, yet the strategic narrative loses sharpness. A startup is not a fund.
- The Moment Biotech Founders Realize the Money Is Gone
Why biotech founders lose financial control without seeing it coming, and what has to be in place early For Biotech Founders, the real danger is not running out of money, but losing financial control early This is where many biotech founders lose visibility. The moment biotech founders lose flexibility is long before the bank account becomes the problem. Decisions get postponed in the hope that the next data readout, the next partnership, or the next funding
- Glyco-sulfo hotspots in the chemokine receptor system
sulfated mCCR2 peptides can outcompete available chemokines, decreasing retinal degradation in mice (Jung
